NEW YORK (GenomeWeb News) – Qiagen and Lilly inked their third companion diagnostic deal this week.

The companies did not disclose the drug or the molecular diagnostic target that the test will gauge.

Qiagen highlighted that the latest deal "builds on a master collaboration agreement for development of tailored therapies in cancer and other therapeutic areas signed earlier this year."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.